1. Home
  2. QUBT vs XGN Comparison

QUBT vs XGN Comparison

Compare QUBT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum Computing Inc.

QUBT

Quantum Computing Inc.

HOLD

Current Price

$6.94

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$3.08

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUBT
XGN
Founded
2001
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
64.5M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
QUBT
XGN
Price
$6.94
$3.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$17.00
$9.14
AVG Volume (30 Days)
8.2M
243.0K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
84.93
N/A
EPS
N/A
N/A
Revenue
$682,000.00
N/A
Revenue This Year
$3,210.56
$8.06
Revenue Next Year
$51.26
$12.93
P/E Ratio
N/A
N/A
Revenue Growth
82.84
N/A
52 Week Low
$5.76
$2.59
52 Week High
$25.84
$12.23

Technical Indicators

Market Signals
Indicator
QUBT
XGN
Relative Strength Index (RSI) 43.40 48.30
Support Level $6.18 $2.59
Resistance Level $7.71 $3.79
Average True Range (ATR) 0.45 0.21
MACD 0.06 0.07
Stochastic Oscillator 49.35 75.00

Price Performance

Historical Comparison
QUBT
XGN

About QUBT Quantum Computing Inc.

Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Share on Social Networks: